University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 10M-17-4


A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.-Fellow
Other Trial Staff:  Lusine Raddatz, D.M., Gina Tse, Coordinator, Kristy Sartor Massopust, Coordinator, Shamim Jhimlee, Coordinator, Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.